208 related articles for article (PubMed ID: 23977262)
1. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1.
Lao X; Liu M; Chen J; Zheng H
PLoS One; 2013; 8(8):e72242. PubMed ID: 23977262
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
[TBL] [Abstract][Full Text] [Related]
3. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects.
Lao X; Li B; Liu M; Shen C; Yu T; Gao X; Zheng H
Apoptosis; 2015 Oct; 20(10):1307-20. PubMed ID: 26283169
[TBL] [Abstract][Full Text] [Related]
4. Increased antitumor activity of tumor-specific peptide modified thymopentin.
Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
[TBL] [Abstract][Full Text] [Related]
5. Expression, purification and characterization of a novel soluble human thymosin alpha1 concatemer exhibited a stronger stimulation on mice lymphocytes proliferation and higher anti-tumor activity.
Li W; Song L; Wu S; Xue X; Zhang L; He L; Han W; Wang Q; Ling R; Zhang W; Yan Z; Zhang Y
Int J Biol Sci; 2011; 7(5):618-28. PubMed ID: 21647330
[TBL] [Abstract][Full Text] [Related]
6. Expression and hydroxylamine cleavage of thymosin alpha 1 concatemer.
Zhou L; Lai ZT; Lu MK; Gong XG; Xie Y
J Biomed Biotechnol; 2008; 2008():736060. PubMed ID: 18645619
[TBL] [Abstract][Full Text] [Related]
7. Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization.
Gao D; Zhang X; Zhang J; Cao J; Wang F
Arch Pharm Res; 2008 Nov; 31(11):1471-6. PubMed ID: 19023544
[TBL] [Abstract][Full Text] [Related]
8. Production of Nα-acetylated thymosin α1 in Escherichia coli.
Ren Y; Yao X; Dai H; Li S; Fang H; Chen H; Zhou C
Microb Cell Fact; 2011 Apr; 10():26. PubMed ID: 21513520
[TBL] [Abstract][Full Text] [Related]
9. Intein-mediated expression, purification, and characterization of thymosin α1-thymopentin fusion peptide in Escherichia coli.
Li J; Zheng L; Li P; Wang F
Protein Expr Purif; 2012 Jul; 84(1):1-8. PubMed ID: 22554820
[TBL] [Abstract][Full Text] [Related]
10. Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris.
Chen JH; Zhang XG; Jiang YT; Yan LY; Tang L; Yin YW; Cheng DS; Chen J; Wang M
Cancer Immunol Immunother; 2010 Sep; 59(9):1335-45. PubMed ID: 20473755
[TBL] [Abstract][Full Text] [Related]
11. Effect of a C-end rule modification on antitumor activity of thymosin α1.
Wang F; Xu C; Peng R; Li B; Shen X; Zheng H; Lao X
Biochimie; 2018 Nov; 154():99-106. PubMed ID: 30096371
[TBL] [Abstract][Full Text] [Related]
12. The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.
Li J; Cheng Y; Zhang X; Zheng L; Han Z; Li P; Xiao Y; Zhang Q; Wang F
Cancer Lett; 2013 Sep; 337(2):237-47. PubMed ID: 23684552
[TBL] [Abstract][Full Text] [Related]
13. [The anti-tumor efforts of thymosin alpha1 on tumor lysate-pulsed dendritic cells in colon cancer in vitro and in vivo].
Ma YL; Zheng Z; Li BD; Xie SJ; Li GX; Yan QH; Cai JH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1046-9. PubMed ID: 17988589
[TBL] [Abstract][Full Text] [Related]
14. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
[TBL] [Abstract][Full Text] [Related]
15. Construction, expression and characterization of human interferon alpha2b-(G4S)n-thymosin alpha1 fusion proteins in Pichia pastoris.
Yang YF; Yuan HY; Liu NS; Chen XL; Gao BY; Lu H; Li YY
World J Gastroenterol; 2005 May; 11(17):2597-602. PubMed ID: 15849818
[TBL] [Abstract][Full Text] [Related]
16. Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs half-life and enhances antitumor effects in vivo.
Shen X; Wang L; Xu C; Yang J; Peng R; Hu X; Wang F; Zheng H; Lao X
Int Immunopharmacol; 2019 Sep; 74():105662. PubMed ID: 31220695
[TBL] [Abstract][Full Text] [Related]
17. Effects on tumor growth and immunosuppression of a modified Tα1 peptide along with its circular dichroism spectroscopy data.
Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
Data Brief; 2018 Oct; 20():126-131. PubMed ID: 30109250
[TBL] [Abstract][Full Text] [Related]
18. Generation of mature Nα-terminal acetylated thymosin α 1 by cleavage of recombinant prothymosin α.
Liu B; Gong X; Chang S; Sun P; Wu J
ScientificWorldJournal; 2013; 2013():387282. PubMed ID: 24288480
[TBL] [Abstract][Full Text] [Related]
19. Proliferative and anti-proliferative effects of thymosin alpha1 on cells are associated with manipulation of cellular ROS levels.
Qin Y; Chen FD; Zhou L; Gong XG; Han QF
Chem Biol Interact; 2009 Aug; 180(3):383-8. PubMed ID: 19442654
[TBL] [Abstract][Full Text] [Related]
20. Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation.
Binsfeld M; Hannon M; Otjacques E; Humblet-Baron S; Baudoux E; Beguin Y; Baron F; Caers J
Cancer Immunol Immunother; 2015 Aug; 64(8):989-98. PubMed ID: 25971542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
